Effects of Intestinal FXR-Related Molecules on Intestinal Mucosal Barriers in Biliary Tract Obstruction

Meng Yan1,2, Li Hou1, Yaoyao Cai1

  • 1Department of Pediatric Surgery, Children's Hospital of Nanjing Medical University, Nanjing, China.

Insights

The farnesoid X receptor (FXR) agonist obeticholic acid (OCA) improves intestinal barrier function and microbiota in bile duct-ligated rats. OCA treatment reduces liver fibrosis and inflammation, promoting gut health by modulating bacterial composition and function.

Area of Science:

  • Gastroenterology and Hepatology
  • Microbiology and Immunology
  • Pharmacology

Background:

  • Farnesoid X receptor (FXR) is crucial for bile acid homeostasis and a therapeutic target for cholestatic liver diseases.
  • The impact of intestinal FXR on the intestinal barrier and microbiota remains incompletely understood.
  • Bile duct ligation (BDL) in rats serves as a model to study cholestatic liver injury and its effects on the gut.

Purpose of the Study:

  • To investigate the role of intestinal FXR activation in response to bile duct ligation.
  • To evaluate the effects of the FXR agonist obeticholic acid (OCA) on intestinal barrier function, inflammation, and microbiota.
  • To assess OCA's impact on liver fibrosis and intestinal epithelial cell apoptosis in a rat model of cholestasis.

Main Methods:

  • Intestinal tissues from patients and bile duct-ligated (BDL) rats treated with OCA or vehicle were analyzed for FXR-related gene expression.
  • Intestinal permeability, morphology, and microbiota composition (16S rDNA sequencing) were assessed in BDL rats.
  • Functional microbial profiling (BugBase, PICRUSt2) and Caco-2 cell apoptosis assays were performed.

Main Results:

  • OCA treatment significantly reduced liver fibrosis and intestinal inflammation in BDL rats.
  • OCA improved intestinal barrier integrity and modulated the gut microbiota, increasing beneficial bacteria and enhancing metabolic function.
  • OCA decreased LPS-induced apoptosis in Caco-2 cells, suggesting a protective effect on intestinal epithelial cells.

Conclusions:

  • Intestinal FXR activation by OCA improves gut barrier function and modulates the intestinal microbiota in cholestatic liver injury.
  • OCA demonstrates therapeutic potential by mitigating liver fibrosis, reducing inflammation, and protecting the intestinal mucosa.
  • FXR agonists represent a promising strategy for managing complications associated with cholestatic liver diseases.

Related Concept Videos

Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
535
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
370
Hepatic Drug Excretion: Influencing Factors01:16

Hepatic Drug Excretion: Influencing Factors

The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
211
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
306
Irritable Bowel Syndrome I: Introduction01:17

Irritable Bowel Syndrome I: Introduction

Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
359
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
176